Rupam Manna/LinkedIn
Aug 17, 2026, 00:33
Rupam Manna: CELMoDs – Next-Generation Molecular-Glue Protein Degraders
Rupam Manna, Postdoctoral Student – DrNB Medical Oncology at National Board of Examinations, shared a post on X:
“CELMoDs: next-generation molecular-glue protein degraders.
By binding cereblon, CELMoDs redirect the CRL4–CRBN E3 ubiquitin ligase toward IKZF1 and IKZF3.
Their proteasomal degradation suppresses IRF4–MYC signalling, promotes myeloma-cell apoptosis and activates T and NK cells.
Key agents:
- Iberdomide – first FDA-approved CELMoD
- Mezigdomide – investigational in multiple myeloma
- Golcadomide – investigational in lymphoma
Remember the major class toxicities: neutropenia, infections, anaemia and thrombocytopenia.”
Stay updated with Hemostasis Today.
-
Oct 2, 2026, 09:20Anticoagulants, Blood Thinners, or Antithrombotic Medications? – World Thrombosis Day
-
Oct 2, 2026, 06:00Susan Wickersham: Gradual Shift towards Autologous Blood Transfusion is a Current Trend
-
Oct 2, 2026, 05:54Shamee Shastry: When Every Cell Reacts – The Hunt for Rare Blood
-
Oct 2, 2026, 05:49David Mclntosh: Expanding Plasma Protein Therapies in Underserved Regions
-
Oct 2, 2026, 05:38Dianne E. van der Wal: C-Terminal Endings Impact PAR1/PAR4 Peptide Potency in In Vitro Platelet Assays
-
Oct 2, 2026, 05:29Mohammed Alo: Your LDL Isn’t a Snapshot – It’s a Smoking Habit Measured in Years
-
Oct 2, 2026, 00:33Marwa Mostafa: Hemoglobinopathies – When Globin Genes Go Wrong
-
Oct 1, 2026, 23:46Behnood Bikdeli: Global Burden of Venous Thromboembolism
-
Oct 1, 2026, 23:46Sthanu Subramanian: Clinical Presentation, Risk Factors, Diagnosis, and Neuroimaging Findings in CVT